A5103158773- Acute Myeloid Leukemia Research
- Gout, Hyperuricemia, Uric Acid
- Hepatitis C virus research
- Hematopoietic Stem Cell Transplantation
- Blood Pressure and Hypertension Studies
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Liver Disease and Transplantation
- Parvovirus B19 Infection Studies
- Vascular Malformations Diagnosis and Treatment
- Case Reports on Hematomas
- Healthcare and Venom Research
- Hormonal Regulation and Hypertension
- Autoimmune and Inflammatory Disorders Research
- Chronic Myeloid Leukemia Treatments
- Cerebral Venous Sinus Thrombosis
- Urticaria and Related Conditions
- Meningioma and schwannoma management
- Bartonella species infections research
- Systemic Lupus Erythematosus Research
- Rheumatoid Arthritis Research and Therapies
- Veterinary medicine and infectious diseases
- Acupuncture Treatment Research Studies
- Sodium Intake and Health
- Musculoskeletal synovial abnormalities and treatments
- Lipid metabolism and disorders
Shuguang Hospital
2019-2025
Shanghai University of Traditional Chinese Medicine
2019-2025
Horizon Therapeutics (United States)
2022-2025
Amgen (United States)
2025
Sichuan Academy of Traditional Chinese Medicine
2024
Fujian Medical University
2022
Sidney Kimmel Comprehensive Cancer Center
2021
Johns Hopkins University
2021
Horizon Therapeutics (United Kingdom)
2021
Takeda (United States)
2014-2018
Clonal hematopoiesis (CH) can be transmitted from a donor to recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on outcomes and graft alloimmune function uncertain.
Abstract Objectives Pegloticase rapidly lowers serum urate in uncontrolled/refractory gout patients, with ≥1 tophus resolution 70% of pegloticase responders and 28% non-responders. Dual-energy computed tomography (DECT) non-invasively detects MSU deposition, including subclinical quantifies volumes depicts bone erosions. This report presents DECT findings MIRROR open-label trial participants receiving pegloticase+MTX co-therapy. Methods Serial scans were obtained during (8 mg biweekly...
Gout is 12-times more prevalent in kidney transplant (KT) recipients than non-transplanted population. We report quality-of-life (QOL) and clinical assessment findings from the PROTECT trial examining pegloticase efficacy safety KT with uncontrolled gout. Patients serum urate (SU) ≥7 mg/dL, oral urate-lowering therapy refractory/intolerant, one of following were enrolled: ≥2 flares/year, unresolving tophi, or chronic gouty arthritis. ≥1 year post-transplant, a graft eGFR ≥15 ml/min/1.73m2...
Publications suggest immunomodulation co-therapy improves responder rates in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR open-label trial showed a 6-month + methotrexate rate of 79%, compared to an established 42% monotherapy rate. Longer-term efficacy/safety data are presented here.
Haemophagocytic lymphohistiocytosis (HLH) is a cytokine-driven inflammatory syndrome caused by uncontrolled hypersecretion of cytokines. Conventional first-line treatment for HLH included HLH-94 and HLH-2004 regimens. However, quite few patients do not respond to or cannot tolerate intensive chemotherapy. We reported two cases HLH, one natural killer (NK)/T-cell lymphoma another associated with missense variants in the perforin 1 gene. They both received ruxolitinib plus dexamethasone...
An open‐label, long‐term study evaluated safety and tolerability of azilsartan medoxomil/chlorthalidone (AZL‐M/CLD) vs olmesartan/hydrochlorothiazide (OLM/HCTZ) in hypertensive participants with stage 3 chronic kidney disease. Initial therapy was AZL‐M/CLD 20/12.5 mg (n = 77) or OLM/HCTZ 76), but could be up‐titrated (AZL‐M/CLD to 40/25 mg; [US] 20/25 [Europe]) other agents added during weeks 4‐52. Primary endpoint proportion ≥ 1 adverse event (AE) through week 52. Baseline demographics were...
To investigate the mechanism and regulation of differentiation from bone marrow mesenchymal stem cells (BMSCs) into hepatocytes to find a new source for therapies hepatic diseases.We isolated BMSCs subsequent in presence hepatocyte growth factor (HGF) or beta-nerve (beta-NGF). Cell morphology was observed cell surface phenotypings were detected by flow cytometry. a1-antitrypsin (AAT) expression confirmed immunocytochemistry albumin validated real time PCR western blotting. The high-affinity...
Uncontrolled/refractory gout patients are recalcitrant/intolerant to oral urate-lowering therapies (ULTs), experiencing frequent flares, functionally limiting tophi, and low quality of life. Pegloticase lowers urate, but anti-pegloticase antibodies limit efficacy increase infusion reaction (IR) risk. Immunomodulator + pegloticase co-administration may improve treatment response rates, with 79% MIRROR open-label trial (MIRROR-OL, methotrexate) participants meeting 6-month criteria....
Patients with grade 2-3 essential hypertension and postplacebo mean clinic systolic blood pressure (SBP) 160-190 mm Hg 24-hour SBP 140-175 by ambulatory monitoring (ABPM) received 40 mg azilsartan medoxomil (AZL-M) monotherapy for 4 weeks. "Nonresponders" were then randomized to 8 weeks of double-blind treatment AZL-M mg, AZL-M/chlortalidone (CLD) 40/25, or AZL-M/CLD 40/12.5 mg. After weeks, change was -21.1 (±1.04) 40/25 -15.8 (±1.08) -6.4 (±1.05) (P < 0.001 both vs AZL-M, ANCOVA). Drug...
The aim of this study was to conduct a comprehensive evaluation the rehydration efficacy QSBYD and elucidate its potential underlying mechanism.
Background Clonal hematopoiesis (CH) can be transmitted from donor to recipient during allogeneic hematopoietic cell transplantation. Exclusion of candidate donors with CH is controversial since its impact on outcomes and graft alloimmune function uncertain. Methods We performed targeted error-corrected sequencing samples 1727 aged 40 or older assessed the effect clinical outcomes. measured long-term engraftment 102 clones cytokine levels in 256 recipients at 3 12 months after transplant....
Abstract Background: Publications suggest immunomodulation co-therapy improves responder rates in uncontrolled/refractory gout patients undergoing pegloticase treatment. The MIRROR open-label trial showed a 6-month pegloticase+methotrexate rate of 79%, compared to an established 42% monotherapy rate. Longer-term efficacy/safety data are presented here. Methods: Uncontrolled (serum urate [SU]≥6 mg/dL and SU≥6 despite urate-lowering therapy [ULT], ULT intolerance, or functionally-limiting...
Objective To investigate the morphological characteristics of superior sagittal sinus (SSS) and bridging vein (BrV) with virtual reality (VR) technology their clinical significances. Methods Forty-three patients parasagittal meningioma (PSM group) 21 trigeminal neuralgia or hemifacial spasm who had no intracranial venous system diseases (normal group), admitted to our hospital from October 2011 March 2013, were chosen. The SSS BrV 2 groups observed, which was finished in VR...
Objective To evaluate the clinical value of collateral venous circulation assessment in operations parasagittal meningiomas (PSM). Methods A total 71 patients with PSM were enrolled this study who underwent surgical at Department Neurosurgery, Fuzhou General Hospital from October 2011 to December 2015. The examination MRV was conducted prior operation reveal location tumors and degrees their invasion sinus. graded 0 4 based on Qureshi Collateral Circulation Assessment certain...
Objective To investigate the effects of Hoxb3 targeting by microRNA218 on migration and epithelial-mesenchymal transition cervical cancer cells. Methods Dual luciferase reporter gene method was used to analyze specificity miRNA-218 for mRNA.Then we constructed a lentiviral vector microRNA-218, packaged lentivirus, infected highly metastatic cell line Caski cancer, established stable microRNA-218 (experimental group) control (control group). The expression Hoxb3, E-cadherin, Vimentin...